The debate revealed fundamental disagreement about whether C1q has spatially distinct functions at synapses versus microglia, or whether outcomes depend solely on binding partners. This mechanistic uncertainty undermines all proposed therapeutic strategies targeting C1q.
Source: Debate session sess_SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1 (Analysis: SDA-2026-04-12-gap-debate-20260410-112848-7ba6c2e1)
This is best treated as a stratification and response-modifier hypothesis rather than a primary C1q mechanism. APOE4 may alter lipid and aggregate surfaces in ways that shift C1q interactomes toward complement-amplifying complexes, but the causal chain remains loose because ApoE biology is highly pleiotropic.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["APOE4 Isoform Structural Instability"]
B["Impaired Lipid Loading Reduced Cholesterol Efflux"]
C["LRP1 Reduced Binding BBB Clearance Deficit"]
D["Amyloid-beta Accumulation"]
E["Synaptic Dysfunction Membrane Disruption"]
F["Neurodegeneration Cognitive Decline"]
G["APOE3 Comparison Normal Lipidation"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"protective"| C
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style F fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#1b5e20,stroke:#81c784,color:#81c784
Median TPM across 13 brain regions for APOE,C1QA,C1QB,C1QC,TREM2,APP from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
9 citations9 with PMID5 mediumValidation: 0%7 supporting / 2 opposing
✓For(7)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
4
3
2
MECH 4CLIN 3GENE 2EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Advancements in APOE and dementia research: Highli…
An integrative analysis of single-cell and bulk transcriptome and bidirectional mendelian randomization analys…MEDIUM▼
An integrative analysis of single-cell and bulk transcriptome and bidirectional mendelian randomization analysis identified C1Q as a novel stimulated risk gene for Atherosclerosis.
ApoE effects may operate mainly through lipid trafficking, plaque compaction, or microglial activation upstrea…▼
ApoE effects may operate mainly through lipid trafficking, plaque compaction, or microglial activation upstream of C1q rather than through direct C1q-complex remodeling.
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-25 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Synaptic C1q drives complement-dependent pruning, while microglial surface-associated C1q biases phagocyte state through receptor-specific signaling
Mechanism: C1q deposited on weak or stressed synapses preferentially nucleates the classical complement cascade (`C1q -> C4 -> C3`), generating opsonins that engage microglial CR3/ITGAM-ITGB2 and promote engulfment. In contrast, C1q bound directly to microglial receptors or pericellular ligands may alter microglial transcriptional state without requiring full downstream complement activation. This would make localization mechanis
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Overall skeptical read: the debate is probably mixing three separable variables that have not been cleanly orthogonalized experimentally: `location`, `ligand identity`, and `receiver-cell state`. The strongest evidence supports synaptic C1q/C3/CR3-mediated pruning in development and AD models, but that does not by itself prove a distinct microglial surface-signaling program for C1q, nor a binding-partner hierarchy that dominates location. Much of the translational logic is still mouse-heavy and disease-model dependent. Key anchors: synaptic pruning by C1q/C3 in development ([PMID: 18083105](ht
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Triage
The ideas worth carrying forward are `6`, `5`, `1`, `2`, `4`, and `7`, in that order. I would drop `3` for now; it is too speculative to support a drug program.
The main translational point is that only one of these is close to a druggable thesis today: `block classical-pathway activation downstream of C1q` rather than trying to solve all C1q biology first. The rest are mostly mechanism, stratification, or endpoint-selection hypotheses.
Feasibility: Highest. This is the cleanest therapeutic hypothesis becaus
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[{"title":"Selective blockade of classical-pathway activation downstream of C1q will reduce synaptotoxic complement amplification while preserving beneficial C1q recognition functions","description":"The most actionable synthesis is that pathogenicity may depend more on conversion of C1q binding into classical-pathway protease activity than on C1q recognition alone. In this model, inhibiting C1r/C1s should attenuate C4/C3-mediated synapse loss and neuroinflammation while preserving some homeostatic debris sensing and cargo recognition by C1q.","target_gene":"C1QA,C1QB,C1QC
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF iPSC-derived microglia from APOE4/4 donors are compared to APOE3/3 iPSC-derived microglia in a co-culture assay with fluorescently labeled C1q protein under amyloid-beta42 challenge conditions (1 µM, 72 hours), THEN APOE4 microglia will exhibit a significantly different C1q co-immunoprecipitation profile with ≥3-fold enrichment of complement cascade proteins (C1R, C3, C4B) relative to APOE3 microglia.
pendingconf: 0.65
Expected outcome: APOE4 microglia C1q interactome will show preferential association with complement amplification proteins (C1R, C3, C4B) compared to APOE3 microglia which will show preferential C1q association with synaptic proteins (GAP43, SYN1, NRXN1)
Falsified by: No statistically significant difference (p > 0.05) in C1q co-immunoprecipitation partners between APOE4 and APOE3 genotypes; or C1q interactomes show identical complement-to-synapse protein ratios within 20% between genotypes.
Method: iPSC-derived microglia from 6 APOE4/4 and 6 APOE3/3 lines (or published dataset from GEO accession), amyloid-beta42 oligomer treatment, FLAG-C1q IP followed by LC-MS/MS, label-free quantification, Benjamini-Hochberg corrected p < 0.05 as significance threshold, experiment completed within 9 months.
IF APP/PS1 mice crossed to APOE4 knock-in mice are compared to APP/PS1 × APOE3 knock-in mice at 9 months of age, THEN APOE4 brains will show significantly elevated (≥2-fold) membrane-bound C1q-C3 complex formation in the hippocampus as measured by native PAGE immunoblot relative to APOE3 brains.
pendingconf: 0.58
Expected outcome: APOE4 mice will have significantly higher C1q-C3 soluble complex concentrations in brain tissue homogenates (ELISA: mean > 800 pg/mg protein vs < 400 pg/mg for APOE3) and increased colocalization of C1q with TREM2+ microglia in plaque-associated regions by 9 months.
Falsified by: APOE4 and APOE3 mice show equivalent (<1.2-fold) C1q-C3 complex levels with overlapping 95% confidence intervals; or APOE4 shows reduced rather than elevated complement complex formation.
Method: APOE4 and APOE3 targeted replacement mice crossed to APP/PS1 (JAX strains), 9-month-old n≥10 per genotype, hippocampus dissection, native PAGE with C1QA/C3 dual immunoblot, Meso Scale Discovery ELISA for C1q-C3 heterocomplexes, unbiased stereology for C1q-TREM2 colocalization, 6-month experimental timeline.